Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05059223 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
A Phase 3 study, sponsored by Axsome Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT05059223 is a Phase 3 study that has completed, run by Axsome Therapeutics. The registered enrollment target is 90 participants.
The verdict
NCT05059223, a Phase 3 study, has completed, sponsored by Axsome Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study is a multi-center, double-blind, placebo-controlled, randomized Phase 3 trial to assess the safety and efficacy of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).
Interventions
- DRUG Placebo
- DRUG AXS-12 (reboxetine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2024-03-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05059223
The ClinicalTrials.gov registry entry for NCT05059223 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axsome Therapeutics, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05059223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05059223 about?
NCT05059223 is a clinical study titled "A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy". This study is a multi-center, double-blind, placebo-controlled, randomized Phase 3 trial to assess the safety and efficacy of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).
What is the current status of trial NCT05059223?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2021-09-15. Estimated completion is 2024-03-15.
What interventions are being tested in trial NCT05059223?
The interventions under investigation include: Placebo (DRUG), AXS-12 (reboxetine) (DRUG).
Who is sponsoring clinical trial NCT05059223?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.